Jacobs Levy Equity Management Inc. Buys New Position in AlloVir, Inc. (NASDAQ:ALVR)

Jacobs Levy Equity Management Inc. bought a new stake in shares of AlloVir, Inc. (NASDAQ:ALVR) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 664,423 shares of the company’s stock, valued at approximately $279,000. Jacobs Levy Equity Management Inc. owned 0.13% of AlloVir at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Northern Trust Corp lifted its position in shares of AlloVir by 0.8% in the 4th quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after acquiring an additional 1,267 shares during the period. Jane Street Group LLC lifted its position in shares of AlloVir by 47.8% in the 4th quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock worth $52,000 after acquiring an additional 39,808 shares during the period. Raymond James Financial Inc. bought a new stake in shares of AlloVir in the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets bought a new stake in shares of AlloVir in the 4th quarter worth approximately $31,000. Finally, Gilead Sciences Inc. bought a new stake in shares of AlloVir in the 4th quarter worth approximately $6,987,000. Institutional investors own 66.05% of the company’s stock.

AlloVir Trading Down 1.7%

Shares of ALVR stock opened at $3.48 on Monday. The stock has a 50 day moving average of $7.21 and a two-hundred day moving average of $9.87. AlloVir, Inc. has a 12 month low of $7.96 and a 12 month high of $24.15. The company has a market capitalization of $17.55 million, a P/E ratio of -0.17 and a beta of 0.63.

About AlloVir

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.